|Dr. Anil R. Diwan||Exec. Chairman, Pres, CEO & Sec.||400k||N/A||1959|
|Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA||Chief Financial Officer||129.6k||N/A||1959|
|Dr. Irach B. Taraporewala||Consultant||N/A||N/A||1956|
|Dr. Randall W. Barton Ph.D.||Chief Scientific Officer & Chief Regulatory Officer||N/A||N/A||1947|
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
NanoViricides, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.